Shots:Chiesi Group has entered into an exclusive global collaboration & license deal with Arbor for ABO-101 in primary hyperoxaluria type 1 (PH1) & a multitarget option to use Arbor’s gene editing platform for developing liver-targeted therapies for rare diseasesAs per the deal, Chiesi will obtain exclusive rights to develop & commercialize ABO-101 for PH1…
Shots:Intellia has reported P-I trial data assessing nexiguran ziclumeran (nex-z) in ATTRv-PN; results were presented at the International ATTR Amyloidosis Meeting 2025 & published in The NEJMSingle dose of nex-z achieved mean TTR reductions of 92% at 24mos. & 90% in 12 pts followed for 36mos. At 24mos., 13/18 pts met ≥4-point mNIS+7 improvement, incl.…
Shots:Intellia Therapeutics completed enrollment in the global P-III (HAELO) study evaluating lonvo-z for treating HAE, finishing within 9mos. since the first patient was dosed in Jan 2025, with nearly half of the participants enrolled from the USThe study P-III (HAELO) study will evaluate the efficacy and safety of lonvo-z in ≥60 adults and…
Get ready for the 3rd Cell & Gene Therapy Research & Development Congress Asia!
Imbued with the latest scientific developments, clinical stage studies, and success stories in the field, the two-day event kicks off on April 10th at Hotel Fort Canning, Singapore. The topics for sessions include emerging technology, regulatory landscapes and ethical considerations, stem…
Shots:Cell and gene therapies provide a promising opportunity to enhance care for unmet healthcare needs. Biopharma companies are actively exploring these therapies across multiple indications to address healthcare gaps in rare and chronic diseasesIn 2023, the cell and gene therapy market was valued at $18.2B and is projected to grow to $117.46B by…
Shots: 2023 had been a great year for the biopharma industry despite several imposed restrictions from the IRA and inflation With several swaying factors impacting the biopharma industry, including social, economic, regulatory and others, some of the noteworthy trends that emerged in 2024 and are shaping the ways biopharma companies operate The article explores four key…

